Skip to content
Peptidepedia

TB-500 Dosage Guide: Protocols, Timing & How Much to Take (2026)

From Peptidepedia, the trusted peptide wiki.

Dosage Protocols

No standardized dosing protocols have been established through clinical trials for human use. The following protocols are derived from anecdotal reports and extrapolation from research settings.

Loading Phase: Conservative protocols recommend 1.0–1.5 mg administered subcutaneously or intramuscularly twice weekly (2–3 mg weekly total), for 4–6 weeks. Some community protocols use higher doses, but no human clinical trial data exists to support specific loading doses.

Maintenance Phase: Following the loading period, dosing typically reduces to 1–2 mg once weekly to maintain therapeutic effects.

Cycling Considerations:

  • Typical active use: 4–6 weeks
  • Common protocol: 4–6 weeks on, 2–4 weeks off before resuming if needed
  • Chronic conditions may require extended or adjusted protocols

Frequently Asked Questions

Most users report initial improvements within 2–4 weeks, with more substantial benefits developing over 4–8 weeks of consistent use. Timelines vary based on injury severity, individual physiology, and dosing protocols.

Clinical trials of thymosin beta-4 have demonstrated that it is safe and well-tolerated at therapeutic doses in animals. However, long-term safety data specifically for TB-500 in humans is limited, and potential risks from unregulated products include contamination and inconsistent dosing.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Goldstein AL, Kleinman HK. Minireview: Crosstalk between thymosin β4 and the chemokine network. Ann N Y Acad Sci. 2015.
  2. Philp D, Kleinman HK. Animal studies with thymosin β4, a multifunctional tissue repair and regeneration peptide. Ann N Y Acad Sci. 2012.
  3. Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999.
  4. Smart N, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007.
  5. RegeneRx Biopharmaceuticals. Phase II Clinical Trials: Thymosin Beta-4 for Dermal Wound Healing.
  6. World Anti-Doping Agency. The 2024 Prohibited List International Standard.
  7. Drip Hydration. The Wolverine Stack: Can BPC 157 and TB 500 Accelerate Injury Recovery?
  8. Examine.com. Thymosin Beta-4 Research Breakdown.
  9. U.S. Food and Drug Administration. Bulk Drug Substances Under Evaluation for Use in Compounding Under Section 503A.
←Read the full TB-500 guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”